Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease

2004 ◽  
Vol 32 (Supplement) ◽  
pp. S266-S270 ◽  
Author(s):  
Elena M. Faioni ◽  
Stefano Ferrero ◽  
Gessica Fontana ◽  
Umberto Gianelli ◽  
Michele M. Ciulla ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Protein C ◽  
Endothelial Protein C Receptor ◽  
Intestinal Tissue ◽  
Inflammatory Bowel

scholarly journals Microbiome Heterogeneity Characterizing Intestinal Tissue and Inflammatory Bowel Disease Phenotype

2016 ◽  
Vol 22 (4) ◽  
pp. 807-816 ◽  
Author(s):  
Andrea D. Tyler ◽  
Richard Kirsch ◽  
Raquel Milgrom ◽  
Joanne M. Stempak ◽  
Boyko Kabakchiev ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Phenotype ◽  
Intestinal Tissue ◽  
Inflammatory Bowel

Plasminogen Activators in the Intestine of Patients with Inflammatory Bowel Disease

1988 ◽  
Vol 60 (02) ◽  
pp. 262-266 ◽  
Author(s):  
P A F de Bruin ◽  
G Crama-Bohbouth ◽  
H W Verspaget ◽  
J H Verheijen ◽  
G Dooijewaard ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Plasminogen Activators ◽  
Intestinal Tissue ◽  
Colonic Adenomas ◽  
Tissue Plasminogen ◽  
Inflammatory Bowel ◽  
The Difference ◽  
Colorectal Cancer Patients

SummaryPlasminogen activators were determined in intestinal tissue, obtained after surgery from patients with Crohn’s disease and ulcerative colitis, and compared with normal intestinal tissue from colorectal cancer patients.The activity and quantity of tissue-plasminogen activator (t-PA) was found to decrease with the severity of inflammation in the patients with inflammatory bowel disease. Urokinase (u-PA) activity, however, was not changed compared with controls or in relation with severity of inflammation. In contrast, the level of u-PA antigen was found to be increased significantly in the inflammatory bowel disease tissues and was also related with severity of inflammation. The difference between u-PA activity and antigen in inflammatory bowel disease tissue could be attributed to an increase in inactive pro-u-PA and u-PA-inhibitor complexes.This increase in u-PA and the concomitant decrease in t-PA, are similar to those found in premalignant colonic adenomas, and might be related to the known increased cancer risk in inflammatory bowel disease.

Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

2015 ◽  
Vol 33 (Suppl. 1) ◽  
pp. 95-104
Author(s):  
Reena Khanna ◽  
Mahmoud H. Mosli ◽  
Brian G. Feagan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Cellular Migration ◽  
Leukocyte Trafficking ◽  
Intestinal Tissue ◽  
Efficacy Data ◽  
Inflammatory Bowel ◽  
Inflammatory Drugs ◽  
Novel Targets

Since the cause of inflammatory bowel disease (IBD) is unknown, therapy has traditionally been based on the empiric use of anti-inflammatory drugs. However, the recent identification of specific mechanisms that regulate cellular migration into inflamed intestinal tissue has provided novel targets for drug development. In this article, we discuss these mechanisms and review emerging safety and efficacy data regarding use of selective inhibitors of leukocyte trafficking for the treatment of IBD.

Sign in / Sign up

Export Citation Format

Share Document